Treatment of established recurrent hepatitis C in liver-transplant recipients with pegylated interferon-alfa-2b and ribavirin therapy

Guy W. Neff, Marzia Montalbano, Christopher B. O'Brien, Seigo Nishida, Kamran Safdar, Pablo A. Bejarano, Amr S. Khaled, Phillip Ruiz, Gabriella Slapak-Green, Mei Lee, Jose Nery, Maria De Medina, Andreas Tzakis, Eugene R. Schiff

Research output: Contribution to journalArticlepeer-review

Abstract

Introduction. The management issues of transplant patients with hepatitis C virus (HCV) are complex, and interferon therapy is often ineffective. We present data from a retrospective review in liver-transplant recipients suffering from HCV recurrence that were treated with pegylated alpha-2b interferon and ribavirin. Methods. A retrospective review of transplant recipients that received combination pegylated alpha-2b interferon (1.5 mcg/kg/wk) and ribavirin (400-600 mg/day) therapy intended for at least 48 weeks. Complications were recorded and included neutropenia (

Original languageEnglish
Pages (from-to)1303-1307
Number of pages5
JournalTransplantation
Volume78
Issue number9
DOIs
Publication statusPublished - Nov 15 2004

Keywords

  • Fulminant hepatic failure
  • Hepatitis B virus
  • Hepatitis C virus
  • Interferon
  • Orthotopic liver transplantation

ASJC Scopus subject areas

  • Transplantation
  • Immunology

Fingerprint Dive into the research topics of 'Treatment of established recurrent hepatitis C in liver-transplant recipients with pegylated interferon-alfa-2b and ribavirin therapy'. Together they form a unique fingerprint.

Cite this